Abbott Laboratories (ABT) Financials
Key financial figures for Abbott Laboratories (Q2 2026).
Abbott reported Q2 2026 net sales of $12.6B (+13.0% reported, +4.8% comparable) with adjusted diluted EPS of $1.31 (GAAP $0.53), and raised FY2026 adjusted EPS guidance to $5.45-$5.60. Q2 2026 net sales of $12.6B, up 13.0% reported / 4.8% comparable; adjusted diluted EPS of $1.31 vs $1.26 a year earlier; GAAP diluted EPS $0.53. Medical Devices led again: Electrophysiology grew low-teens, Rhythm Management high-single-digits; Diabetes Care (FreeStyle Libre CGM) reaccelerated to 9.5% comparable growth as guided. Diagnostics revenue reached $3.1B on the first full quarter of Exact Sciences, with Cologuard up mid-teens. Abbott raised FY2026 adjusted EPS guidance to $5.45-$5.60 (from $5.38-$5.58) and reaffirmed 6.5-7.5% comparable sales growth guidance. On the outlook: Abbott raised full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60 (from $5.38-$5.58) and reaffirmed comparable sales growth guidance of 6.5-7.5%. Figures are for Q2 2026, as Abbott Laboratories reported them.
- Revenue
- $12.6B
- Net Income
- $928M
- EPS
- $0.53
- Total Assets
- $109.2B
- Operating Cash Flow
- $2.5B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $12.6B | $928M | $0.53 | 14.15% | |
| Q1 FY2026 | $11.2B | $1.1B | $0.62 | 16.5% | $916M |
| Q4 FY2025 | $11.5B | $1.8B | $1.02 | 19.64% | $2.6B |
| Q3 FY2025 | $11.4B | $1.6B | $0.94 | 18.09% | $2.3B |
| Q2 FY2025 | $11.1B | $1.8B | $1.01 | 18.42% | $1.5B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $44.3B | $6.5B | $3.72 | 18.16% | $7.4B |
| FY2024 | $42.0B | $13.4B | $7.64 | 16.27% | $6.4B |
| FY2023 | $40.1B | $5.7B | $3.27 | 16.04% | $5.1B |
Frequently asked questions
What was Abbott Laboratories's revenue last quarter?
Abbott Laboratories reported revenue of $12.59 billion for Q2 FY2026, up 13.0% from the same period a year earlier.
Is Abbott Laboratories profitable?
Yes. Abbott Laboratories reported net income of $928.0 million for Q2 FY2026, a net margin of 7.37% on revenue.
How has Abbott Laboratories's margin trended?
Operating margin was 14.15% in Q2 FY2026, compared with 18.42% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
When does Abbott Laboratories report next?
Abbott Laboratories is scheduled to report results on 2026-10-21. The company has confirmed that date.
Full income statement, balance sheet and cash flow for Abbott Laboratories on SentiSense, with up to forty quarters and twenty fiscal years of history.